Stocks · Healthcare · Biotechnology
Xeris Biopharma Holdings, Inc. XERS
$10.13 +11.56% Close, Oct 5, 2026 · NASDAQ · Market cap $1.57B
High quality
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin widened to 10.9% from -4.0% a year earlier.
- Revenue over the last four quarters was $335.4M, up 36.3% from a year earlier, slowing from 41.5% a quarter earlier.
- The diluted share count rose 10.8% in a year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 21%
- Revenue growth, 3-year CAGRTop 17%
- Revenue growth accelerationBottom 25%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 12%
- Gross marginTop 27%
- Operating marginTop 25%
- Accruals (lower is better)Top 17%
- Net debt / EBITDA (lower is better)Bottom 6%
- Interest coverTop 40%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 32%
- Free-cash-flow yieldTop 23%
- EBITDA / enterprise valueTop 35%
- Sales / enterprise valueBottom 46%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 38%
- 6-month returnTop 15%
- 1-year return vs S&P 500Top 43%
- Distance from 52-week highTop 20%
- Trend checklist (0–4)Top 10%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 5%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 26%
- Upside to consensus price targetBottom 41%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 49%
- Maximum drawdown, 3 yearsTop 21%
- Beta vs S&P 500 (lower is better)Top 47%
- Net debt / EBITDA (lower is better)Bottom 6%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 41.5% | 36.3% | ↓ |
| Gross margin | 81.1% | 83.3% | ↑ |
| Operating margin | -4.0% | 10.9% | ↑ |
| FCF margin | -6.8% | 16.5% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 36.3% | 41.5% | ↓ | Top 21% |
| Gross margin | 83.3% | 81.1% | ↑ | Top 27% |
| Operating margin | 10.9% | -4.0% | ↑ | Top 25% |
| Net margin | -5.1% | -13.0% | ↑ | — |
| Free-cash-flow margin | 16.5% | -6.8% | ↑ | — |
| Return on invested capital | 12.5% | — | Top 12% | |
| Revenue growth, 3-year CAGR | 38.3% | — | Top 17% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -17.9%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 8.4%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -26.8 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 10.22×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 1.3×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 0.16%
- Shareholder yield
- 0.16%
- Share count change, 1 year
- +10.8%
- Share count change, 3-year CAGR
- +8.0%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 6 of 8
- Average EPS surprise, last 4
- -100.0%
- Average 2-day reaction, last 8
- +2.4%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $14.00
- Target vs current price
- +38.2%
- Analysts with a rating
- 11
- Share rating Buy or Strong Buy
- 91%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | -1582.7% | -9.2% | +4.7% | +5.8% | — |
| May 7, 2026 | +465.0% | +4.1% | +0.9% | -3.5% | +27.6% |
| Mar 2, 2026 | +100.0% | -1.6% | -5.1% | -11.8% | +2.3% |
| Nov 6, 2025 | -65.0% | -21.9% | -23.1% | -31.9% | -25.6% |
| Aug 7, 2025 | +66.7% | +20.2% | +32.6% | +43.7% | +76.9% |
| May 8, 2025 | +14.3% | +15.2% | +3.6% | -0.4% | +24.1% |
| Mar 6, 2025 | +62.5% | +9.5% | +21.2% | +36.6% | +31.0% |
| Nov 8, 2024 | +33.3% | +3.3% | -9.2% | +9.2% | +7.7% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.18 | $0.01 | -1582.7% | $91.0M |
| May 7, 2026 | $0.01 | -$0.00 | +465.0% | $82.5M |
| Mar 2, 2026 | $0.06 | $0.03 | +100.0% | $85.8M |
| Nov 6, 2025 | $0.00 | $0.01 | -65.0% | $74.4M |
| Aug 7, 2025 | -$0.01 | -$0.03 | +66.7% | $71.5M |
| May 8, 2025 | -$0.06 | -$0.07 | +14.3% | $60.1M |
| Mar 6, 2025 | -$0.03 | -$0.08 | +62.5% | $60.1M |
| Nov 8, 2024 | -$0.06 | -$0.09 | +33.3% | $52.9M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / EBITDA | 105.7× | — | — | Top 35% |
| EV / Sales | 5.17× | — | — | Bottom 46% |
| Free-cash-flow yield | 3.53% | — | — | Top 23% |
| Earnings yield | -1.02% | — | — | Top 32% |
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 11
- Days above the 200-day average
- 73
- 50-day average slope (20 days)
- +1.2%
- 200-day average slope (20 days)
- +2.4%
- Distance from 50-day average
- +19.3%
- Distance from 200-day average
- +40.5%
- RSI (14)
- 67.2
- Relative volume
- 1.33×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 55.5%
- Volatility vs own 5-year history
- 29th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.07
- Correlation with S&P 500
- 0.29
- Current drawdown from 1-year high
- +0.0%
- Maximum drawdown, 3 years
- -47.2%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 9, 2021 | Jan 5, 2023 | -86.2% | 480 days | 654 days (Aug 15, 2025) |
| Nov 4, 2025 | Mar 24, 2026 | -46.6% | 95 days | 130 days (Sep 29, 2026) |
| Oct 8, 2020 | Dec 9, 2020 | -34.8% | 43 days | 38 days (Feb 4, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $1.57B
- EPS, diluted (TTM)
- -$0.10
- Revenue (TTM)
- $335.4M
- 52-week range
- $5.25 – $11.33
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $49.6M | $110.2M | $163.9M | $203.1M | $291.8M |
| Gross profit | $36.3M | $87.6M | $135.3M | $166.2M | $238.4M |
| Operating income | -$115.2M | -$81.9M | -$44.0M | -$33.6M | $24.9M |
| Net income | -$122.7M | -$94.7M | -$62.3M | -$54.8M | $554,000 |
| EPS (diluted) | -$1.55 | -$0.70 | -$0.45 | -$0.37 | $0.00 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $54.3M | $60.1M | $60.1M | $71.5M | $74.4M | $85.8M | $83.1M | $92.1M |
| Net income | -$15.7M | -$5.1M | -$9.2M | -$1.9M | $621,000 | $11.1M | $2.2M | -$31.1M |
| EPS (diluted) | -$0.11 | -$0.03 | -$0.06 | -$0.01 | $0.00 | $0.06 | $0.01 | -$0.18 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$95.5M | -$102.9M | -$47.0M | -$37.0M | $28.6M |
| Capital expenditure | -$1.1M | -$524,000 | -$2.3M | -$868,000 | -$696,000 |
| Free cash flow | -$96.6M | -$103.4M | -$49.3M | -$37.8M | $27.9M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $27.3M | $30.4M | -$428,000 | -$3.7M | $2.2M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $121.7M
- Total assets
- $411.9M
- Total liabilities
- $421.6M
- Total debt
- $289.4M
- Net debt
- $167.7M
- Shareholders’ equity
- -$9.7M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 8,058,977
- Days to cover
- 4.83
- Change vs previous report
- +0.2%
FINRA short interest, settlement date Sep 15, 2026.